Functional neurologic disorder

EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria

Retrieved on: 
星期二, 十月 17, 2023
Incidence, Schizophrenia, LOF, Clinical Global Impression, PANSS, Safety, CEST, Positive, Evenamide, TRS, Strauss, CNS, Peripheral nervous system, Psychosis, Level, XETRA, ECNP, Patient, Pharmaceutical industry, Nursing, Functional neurologic disorder

Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria

Key Points: 
  • Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
    The issuer is solely responsible for the content of this announcement.
  • 95% of patients completed six weeks of treatment, 94% of the completers chose to continue with evenamide treatment into the long-term extension study (Study 015) and 92% of them reached six months of treatment.
  • In contrast to common clinical experience, no patients experienced worsening of their psychoses; consequently, no patients relapsed.
  • Review of the efficacy data indicated that treatment with evenamide resulted in approximately 40% of patients, at six months, no longer meeting the protocol severity criteria used to diagnose treatment resistance.

With 5.41% CAGR, Molecular Imaging Market Size to Hit USD 7.3 Billion by 2032 | Future Market Insights

Retrieved on: 
星期三, 九月 14, 2022
Photon, Siemens, Single-photon emission computed tomography, Conditional sentence, Siemens Healthineers, Adoption, Health, Cardiology, Time, Molecular imaging, Gynaecology, Hospital, Philips, Prevalence, Functional neurologic disorder, Acquisition, Growth, Biotelemetry, Isotopia Festival, Industry, Deep learning, Canon Medical Systems Corporation, Lung cancer, PET, Degenerative disease, Cancer, Lung nodule, Bruker, Technology, FMI, Lists of diseases, Market, CT, Diagnosis, SPECT, Health care, Awareness, Lists of countries and territories, Globe, Radiology, Positron emission tomography, CAGR, Agriculture, Medical imaging, Fine chemical, Renewable energy, Software

NEWARK, Del., Sept. 14, 2022 /PRNewswire/ -- The global molecular imaging market is anticipated to value at US$ 7.3 Billion while expanding at a CAGR of 5.41% during the forecast period of 2022-2032. The growth of the market can be attributed to the increasing incidences of chronic illness across the globe.

Key Points: 
  • Growing Adoption of AI-Based Technology in the Healthcare Sector to Expand the Molecular Imaging Market at a CAGR of 5.41% by 2032.
  • In Europe, the molecular imaging market is expected to display a CAGR of 4% during the forecast period.
  • Key Takeaways from the Market Study:
    The global molecular imaging market is expected to secure US$ 4.309 Billion in 2022.
  • Future Market Insights,in its new offering, presents an unbiased analysis of the global molecular imaging market, presenting a historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

Most COVID-19 Patients Have Long-term Neurological Problems

Retrieved on: 
星期一, 五月 24, 2021
Psychiatric diagnosis, Medicine, Clinical medicine, Sleep disorder, Major depressive disorder, Branches of biology, Conversion disorder, Functional neurologic disorder

In a surprise, however, a research team at NYU Grossman School of Medicine also found that 91 percent of patients, whether or not they had a neurological diagnosis when first hospitalized, had such problems six months after going home.

Key Points: 
  • In a surprise, however, a research team at NYU Grossman School of Medicine also found that 91 percent of patients, whether or not they had a neurological diagnosis when first hospitalized, had such problems six months after going home.
  • Among the first prospective studies on COVID-19 neurology, the study also found that patients in the neurological symptom group experienced over time significantly more anxiety, depression, fatigue and sleep problems as measured by standard phone questionnaires (NIH PROMIS/NeuroQoL surveys).
  • Specifically, 94 percent of patients with initial symptoms had abnormal six-month testing, compared to 88 percent of patients without original neurological symptoms, for an average of 91 percent having such symptoms across both groups.
  • Mortality was roughly the same, at about 20 percent, for both groups of patients, whose average age was 68.